LEADER 00867nac# 22002171i 450 001 UON00175681 005 20231205103111.846 100 $a20030730d1958 |0itac50 ba 102 $aUS 105 $a|||| ||||| 110 $ab|||||||||| 200 1 $a Dramabooks 210 $aNew York$cHill and Wang. 463 1$1001UON00423536$12001 $aˆThe ‰Fervent years$ethe story of the group theatre and the thirties$fHarold Clurman$1210 $aNew York$cHill and Wang$d1968$1215 $axiv, 302 p.$d19 cm. 463 1$1001UON00219599$12001 $aPapers on acting$fedited by Brander Matthews$gwith a preface by Henry W. Wells$1210 $aNew York$cHill and Wang$d1958. viii$d303 p. ; 19 cm. 620 $aUS$dNew York$3UONL000050 712 $aHILL and WANG$3UONV266771$4650 801 $aIT$bSOL$c20240220$gRICA 912 $aUON00175681 996 $aDramabooks$91844381 997 $aUNIOR LEADER 04770nam 2200721 a 450 001 9910966870103321 005 20251017110109.0 010 $a9786612644870 010 $a9780309156486 010 $a0309156483 010 $a9781282644878 010 $a1282644874 010 $a9780309150255 010 $a0309150256 035 $a(CKB)2670000000040023 035 $a(EBL)3378620 035 $a(SSID)ssj0000426426 035 $a(PQKBManifestationID)11261967 035 $a(PQKBTitleCode)TC0000426426 035 $a(PQKBWorkID)10373035 035 $a(PQKB)11063276 035 $a(Au-PeEL)EBL3378620 035 $a(CaPaEBR)ebr10395834 035 $a(CaONFJC)MIL264487 035 $a(OCoLC)923281822 035 $a(MiAaPQ)EBC3378620 035 $a(Perlego)4736342 035 $a(DNLM)1537597 035 $a(EXLCZ)992670000000040023 100 $a20100803d2010 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe Public Health Emergency Medical Countermeasures Enterprise $einnovative strategies to enhance products from discovery through approval : workshop summary /$fTheresa Wizemann, Clare Stroud and Bruce M. Altevogt ; Forum on Medical and Public Health Preparedness for Catastrophic Events, Forum on Drug Discovery, Development and Translation, Board on Health Sciences Policy 205 $a1st ed. 210 $aWashington, D.C. $cNational Academies Press$d2010 215 $a1 online resource (194 p.) 225 0 $aThe national academies 300 $aDescription based upon print version of record. 311 08$a9780309150248 311 08$a0309150248 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Contents""; ""INTRODUCTION""; ""BACKGROUND""; ""PARTNERS IN A SINGLE MISSION, DIVERSE CONCERNS AND CHALLENGES""; ""EXAMPLES OF SUCCESSFUL COUNTERMEASURES DEVELOPMENT AND DEPLOYMENT""; ""PARTNERSHIPS AND ALTERNATIVE BUSINESS MODELS""; ""ENGAGING INDUSTRY""; ""NEW PARADIGMS, STRATEGIES, AND TACTICS FOR ENHANCING THE COUNTERMEASURES DEVELOPMENT ENTERPRISE""; ""EXISTING REGULATORY TOOLS AND APPROACHES THAT CAN BE APPLIED TO ADVANCE COUNTERMEASURES DEVELOPMENT""; ""CONCLUSION""; ""Appendix A: References""; ""Appendix B: Workshop Agenda"" 327 $a""Appendix C: Registered Workshop Attendees""""Appendix D: Case Studies of HHS Chemical, Biological, Radiological, and Nuclear Medical Countermeasure Development Programs, Executive Summary""; ""Appendix E: Synthesis of Business Models and Economic and Market Incentives for Vaccines and Therapeutics"" 330 $a"During public health emergencies such as pandemic influenza outbreaks or terrorist attacks, effective vaccines, drugs, diagnostics, and other medical countermeasures are essential to protecting national security and the public's well-being. The Public Health Emergency Medical Countermeasures Enterprise (PHEMCE--a partnership among federal, state, and local governments; industry; and academia) is at the forefront of the effort to develop and manufacture these countermeasures. However, despite the PHEMCE's many successes, there are still serious challenges to overcome. Government-funded medical research is not always focused on countermeasures for the most serious potential threats, and it is difficult to engage pharmaceutical and biotechnology companies to develop and manufacture medical countermeasures that have a limited commercial market. At the request of the Secretary of the U.S. Department of Health and Human Services and the Assistant Secretary for Preparedness and Response, the IOM held a workshop February 22-24, 2010, to address challenges facing the PHEMCE. Workshop participants discussed federal policies and procedures affecting the research, development, and approval of medical countermeasures and explored opportunities to improve the process and protect Americans' safety and health"--National Academies Press description. 606 $aEmergency medicine$vCongresses 615 0$aEmergency medicine 676 $a362.1 701 $aWizemann$b Theresa M$0890630 701 $aStroud$b Clare$01601279 701 $aAltevogt$b Bruce M$01791694 712 02$aInstitute of Medicine (U.S.).$bForum on Medical and Public Health Preparedness for Catastrophic Events. 712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation. 712 02$aInstitute of Medicine (U.S.).$bBoard on Health Sciences Policy. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910966870103321 996 $aThe Public Health Emergency Medical Countermeasures Enterprise$94355018 997 $aUNINA